EQS-News

Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution - Seite 3

"Testing has a key role in getting us back to an old normal," said Goh. "However, PCR tests are often too expensive and slow for many use cases, and antigenic approaches may not be sensitive enough especially in critical cases such as manufacturing, tourism, and leisure, etc. To that end, AptameX is well positioned as an affordable, highly sensitive, and user-friendly alternative."

To finance the operations, the Company raised capital through the use of market based convertible notes from Negma Group Limited and Yorkville Capital Management LLC and moved to a placement with smart money investors in August 2022. To facilitate the capital issue, the Company has received share lending support from current strategic investors including Heracles Investment Group, PT Media Nusantra Citra TBK and Negma Group to facilitate additional fundraising. Further capital issues will require the Company to issue a prospectus in Q2 2022.

In 2022, Achiko looks to further the company's growth, proceeding to AptameX trials in other countries, completing its CE Mark registration to bring AptameX to other parts of Asia, the Middle East and northern Africa (MENA), and eastern Europe, replicating its current production model in new markets. Earlier this month, samples of AptameX second-generation test kits were sent to these locations for product sampling with demonstrations to be held this month. The Company is looking at commercial availability in Q1 2022 in Europe and elsewhere.

"In 2022, we're looking forward to consolidating gains we've made in 2021, enhancing the Board and Management, commercialisation of AptameX beyond Indonesia and adding other complementary aptamer diagnostic products and services," added Goh.

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; ISIN CH0522213468; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company's lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.